相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Prevention of L-Dopa-Induced Dyskinesias by MPEP Blockade of Metabotropic Glutamate Receptor 5 Is Associated with Reduced Inflammation in the Brain of Parkinsonian Monkeys
Marc Morissette et al.
CELLS (2022)
Non-dopaminergic approaches to the treatment of motor complications in Parkinson's disease
M. Angela Cenci et al.
NEUROPHARMACOLOGY (2022)
The multimodal serotonin compound Vilazodone alone, but not combined with the glutamate antagonist Amantadine, reduces L-DOPA-induced dyskinesia in hemiparkinsonian rats
Sophie R. Cohen et al.
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR (2022)
The effects of Vilazodone, YL-0919 and Vortioxetine in hemiparkinsonian rats
Samantha Smith et al.
PSYCHOPHARMACOLOGY (2022)
Microvascular Changes in Parkinson's Disease- Focus on the Neurovascular Unit
Gesine Paul et al.
FRONTIERS IN AGING NEUROSCIENCE (2022)
Sex Differences in Parkinson's Disease: From Bench to Bedside
Maria Claudia Russillo et al.
BRAIN SCIENCES (2022)
Shedding light on dyskinesias
Ivan Castela et al.
EUROPEAN JOURNAL OF NEUROSCIENCE (2021)
NEWLY SYNTHESIZED AMANTADINE DERIVATIVE: SAFETY AND NEUROPHARMACOLOGICAL ACTIVITY
Ivanka Stankova et al.
FARMACIA (2021)
Human α-synuclein overexpression in a mouse model of Parkinson's disease leads to vascular pathology, blood brain barrier leakage and pericyte activation
Osama Elabi et al.
SCIENTIFIC REPORTS (2021)
Role of 5-HT1A Receptor in Vilazodone-Mediated Suppression of L-DOPA-Induced Dyskinesia and Increased Responsiveness to Cortical Input in Striatal Medium Spiny Neurons in an Animal Model of Parkinson's Disease
Feras Altwal et al.
MOLECULES (2021)
Genetic variants in levodopa-induced dyskinesia (LID): A systematic review and meta-analysis
Marika Falla et al.
PARKINSONISM & RELATED DISORDERS (2021)
Neuroinflammation and L-dopa-induced abnormal involuntary movements in 6-hydroxydopamine-lesioned rat model of Parkinson's disease are counteracted by combined administration of a 5-HT1A/1B receptor agonist and A2A receptor antagonist
Annalisa Pinna et al.
NEUROPHARMACOLOGY (2021)
Ondansetron, a highly selective 5-HT3 receptor antagonist, reduces L-DOPA-induced dyskinesia in the 6-OHDA-lesioned rat model of Parkinson's disease
Cynthia Kwan et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2020)
D1-mGlu5 heteromers mediate noncanonical dopamine signaling in Parkinson's disease
Irene Sebastianutto et al.
JOURNAL OF CLINICAL INVESTIGATION (2020)
Distinct anti-dyskinetic effects of amantadine and group II metabotropic glutamate receptor agonist LY354740 in a rodent model: An electrophysiological perspective
Cong Zheng et al.
NEUROBIOLOGY OF DISEASE (2020)
Tapentadol Prevents Motor Impairments in a Mouse Model of Dyskinesia
Rita L. Vaz et al.
NEUROSCIENCE (2020)
6-Hydroxydopamine lesion and levodopa treatment modify the effect of buspirone in thesubstantia nigra pars reticulata
Sergio Vegas-Suarez et al.
BRITISH JOURNAL OF PHARMACOLOGY (2020)
Striatal Kir2 K+ channel inhibition mediates the antidyskinetic effects of amantadine
Weixing Shen et al.
JOURNAL OF CLINICAL INVESTIGATION (2020)
Research advances on L-DOPA-induced dyskinesia: from animal models to human disease
Xi Chen et al.
NEUROLOGICAL SCIENCES (2020)
The selective 5-HT1A receptor agonist, NLX-112, exerts anti-dyskinetic and anti-parkinsonian-like effects in MPTP-treated marmosets
Ria Fisher et al.
NEUROPHARMACOLOGY (2020)
μ Opioid Receptor Agonism for L-DOPA-Induced Dyskinesia in Parkinson's Disease
Erwan Bezard et al.
JOURNAL OF NEUROSCIENCE (2020)
The Multimodal Serotonergic Agent Vilazodone Inhibits L-DOPA-Induced Gene Regulation in Striatal Projection Neurons and Associated Dyskinesia in an Animal Model of Parkinson's Disease
Feras Altwal et al.
CELLS (2020)
L-DOPA-Induced Dyskinesia in a Genetic Drosophila Model of Parkinson's Disease
Joshua A. Blosser et al.
EXPERIMENTAL NEUROBIOLOGY (2020)
Highly-selective μ-opioid receptor antagonism does not block L-DOPA-induced dyskinesia in a rodent model
Mitchell J. Bartlett et al.
BMC RESEARCH NOTES (2020)
The effects of zonisamide on L-DOPA-induced dyskinesia in Parkinson's disease model mice
Hiromi Sano et al.
NEUROCHEMISTRY INTERNATIONAL (2019)
Eltoprazine prevents levodopa-induced dyskinesias by reducing causal interactions for theta oscillations in the dorsolateral striatum and substantia nigra pars reticulate
Qiang Wang et al.
NEUROPHARMACOLOGY (2019)
Pathophysiological clues to therapeutic applications of glutamate mGlu5 receptor antagonists in levodopa-induced dyskinesia
Shayan Pourmirbabaei et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2019)
Parkinson's Disease in Women and Men: What's the Difference?
Silvia Cerri et al.
JOURNAL OF PARKINSONS DISEASE (2019)
Non-human primate models of PD to test novel therapies
Marc Morissette et al.
JOURNAL OF NEURAL TRANSMISSION (2018)
Levodopa Treatment and Dendritic Spine Pathology
Haruo Nishijima et al.
MOVEMENT DISORDERS (2018)
Signal transduction in L-DOPA-induced dyskinesia: from receptor sensitization to abnormal gene expression
Giada Spigolon et al.
JOURNAL OF NEURAL TRANSMISSION (2018)
Synaptic plasticity and levodopa-induced dyskinesia: electrophysiological and structural abnormalities
Barbara Picconi et al.
JOURNAL OF NEURAL TRANSMISSION (2018)
Predictive Value of Parkinsonian Primates in Pharmacologic Studies: A Comparison between the Macaque, Marmoset, and Squirrel Monkey
Nicolas Veyres et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2018)
Animal Models of L-Dopa-Induced Dyskinesia in Parkinson's Disease
M. Angela Cenci et al.
MOVEMENT DISORDERS (2018)
Effects of the Serotonin 5-HT1A Receptor Biased Agonists, F13714 and F15599, on Striatal Neurotransmitter Levels Following l-DOPA Administration in Hemi-Parkinsonian Rats
Adrian Newman-Tancredi et al.
NEUROCHEMICAL RESEARCH (2018)
The effect of mianserin on the severity of psychosis and dyskinesia in the parkinsonian marmoset
Adjia Hamadjida et al.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2018)
Pharmacokinetic/Pharmacodynamic Correlation Analysis of Amantadine for Levodopa-Induced Dyskinesia
Elizabeth F. Brigham et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2018)
An mGlu4-Positive Allosteric Modulator Alleviates Parkinsonism in Primates
Delphine Charvin et al.
MOVEMENT DISORDERS (2018)
The combination of the opioid glycopeptide MMP-2200 and a NMDA receptor antagonist reduced L-DOPA-induced dyskinesia and MMP-2200 by itself reduced dopamine receptor 2-like agonist-induced dyskinesia
Andrew J. Flores et al.
NEUROPHARMACOLOGY (2018)
Diverse serotonin actions of vilazodone reduce l-3,4-dihidroxyphenylalanine-induced dyskinesia in hemi-parkinsonian rats
Samantha M. Meadows et al.
MOVEMENT DISORDERS (2018)
PBF509, an Adenosine A2A Receptor Antagonist With Efficacy in Rodent Models of Movement Disorders
Fabiana Nunez et al.
FRONTIERS IN PHARMACOLOGY (2018)
Validation of a New Scoring Scale for Behavioral Assessment of L-Dopa-Induced Dyskinesia in the Rat: A New Tool for Early Decision-Making in Drug Development
Simon Loiodice et al.
ACS CHEMICAL NEUROSCIENCE (2018)
L-DOPA-Induced Motor Impairment and Overexpression of Corticostriatal Synaptic Components Are Improved by the mGluR5 Antagonist MPEP in 6-OHDA-Lesioned Rats
Yixian Huang et al.
ASN NEURO (2018)
A preclinical study on the combined effects of repeated eltoprazine and preladenant treatment for alleviating L-DOPA-induced dyskinesia in Parkinson's disease
Wai Kin D. Ko et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2017)
Characterizing the differential roles of striatal 5-HT1A auto- and hetero-receptors in the reduction of L-DOPA-induced dyskinesia
Samantha M. Meadows et al.
EXPERIMENTAL NEUROLOGY (2017)
Chemogenetic stimulation of striatal projection neurons modulates responses to Parkinson's disease therapy
Cristina Alcacer et al.
JOURNAL OF CLINICAL INVESTIGATION (2017)
Rabphilin 3A: A novel target for the treatment of levodopa-induced dyskinesias
Jennifer Stanic et al.
NEUROBIOLOGY OF DISEASE (2017)
The effect of mirtazapine on dopaminergic psychosis and dyskinesia in the parkinsonian marmoset
Adjia Hamadjida et al.
PSYCHOPHARMACOLOGY (2017)
Parkinson disease
Werner Poewe et al.
NATURE REVIEWS DISEASE PRIMERS (2017)
Antidyskinetic effect of A2A and 5HT1A/1B receptor ligands in two animal models of Parkinson's disease
Annalisa Pinna et al.
MOVEMENT DISORDERS (2016)
Modulation of serotonergic transmission by eltoprazine in L-DOPA-induced dyskinesia: Behavioral, molecular, and synaptic mechanisms
Veronica Ghiglieri et al.
NEUROBIOLOGY OF DISEASE (2016)
The novel 5-HT1A, receptor agonist, NLX-112 reduces L-DOPA-induced abnormal involuntary movements in rat: A chronic administration study with microdialysis measurements
Andrew C. McCreary et al.
NEUROPHARMACOLOGY (2016)
Antidyskinetic Effect of 7-Nitroindazole and Sodium Nitroprusside Associated with Amantadine in a Rat Model of Parkinson's Disease
Mariza Bortolanza et al.
NEUROTOXICITY RESEARCH (2016)
Advantages of nonhuman primates as preclinical models for evaluating stem cell-based therapies for Parkinson's disease
Douglas A. Grow et al.
STEM CELL RESEARCH (2016)
Maladaptive Synaptic Plasticity in L-DOPA-Induced Dyskinesia
Qiang Wang et al.
FRONTIERS IN NEURAL CIRCUITS (2016)
Evaluation of Models of Parkinson's Disease
Shail A. Jagmag et al.
FRONTIERS IN NEUROSCIENCE (2016)
Dual -agonist/-antagonist opioid receptor modulation reduces levodopa-induced dyskinesia and corrects dysregulated striatal changes in the nonhuman primate model of Parkinson disease
Lisa F. Potts et al.
ANNALS OF NEUROLOGY (2015)
NR2B antagonist CP-101,606 inhibits NR2B phosphorylation at tyrosine-1472 and its interactions with Fyn in levodopa-induced dyskinesia rat model
Min Kong et al.
BEHAVIOURAL BRAIN RESEARCH (2015)
Effect of selective and non-selective serotonin receptor activation on L-DOPA-induced therapeutic efficacy and dyskinesia in parkinsonian rats
E. Tronci et al.
BEHAVIOURAL BRAIN RESEARCH (2015)
A new quantitative rating scale for dyskinesia in nonhuman primates
Lisa F. Potts et al.
BEHAVIOURAL PHARMACOLOGY (2015)
The adenosine A2A receptor antagonist, istradefylline enhances the anti-parkinsonian activity of low doses of dopamine agonists in MPTP-treated common marmosets
Shin-ichi Uchida et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2015)
NLX-112, a novel 5-HT1A receptor agonist for the treatment of L-DOPA-induced dyskinesia: Behavioral and neurochemical profile in rat
H. Iderberg et al.
EXPERIMENTAL NEUROLOGY (2015)
Dual target strategy: combining distinct non-dopaminergic treatments reduces neuronal cell loss and synergistically modulates l-DOPA-induced rotational behavior in a rodent model of Parkinson's disease
Marie-Therese Fuzzati-Armentero et al.
JOURNAL OF NEUROCHEMISTRY (2015)
Disease-Modifying Strategies for Parkinson's Disease
Lorraine V. Kalia et al.
MOVEMENT DISORDERS (2015)
Modeling dyskinesia in animal models of Parkinson disease
Nicolas Morin et al.
EXPERIMENTAL NEUROLOGY (2014)
Modeling Parkinson's disease in monkeys for translational studies, a critical analysis
Lisa F. Potts et al.
EXPERIMENTAL NEUROLOGY (2014)
The mGluR5 Negative Allosteric Modulator Dipraglurant Reduces Dyskinesia in the MPTP Macaque Model
Erwan Bezard et al.
MOVEMENT DISORDERS (2014)
Levodopa-induced dyskinesias are associated with transient downregulation of cAMP and cGMP in the caudate-putamen of hemiparkinsonian rats: Reduced synthesis or increased catabolism?
Giuseppe Sancesario et al.
NEUROCHEMISTRY INTERNATIONAL (2014)
Pharmacological treatments inhibiting levodopa-induced dyskinesias in MPTP-lesioned monkeys: brain glutamate biochemical correlates
Nicolas Morin et al.
FRONTIERS IN NEUROLOGY (2014)
ANIMAL MODELS OF L-DOPA-INDUCED DYSKINESIA: AN UPDATE ON THE CURRENT OPTIONS
H. Iderberg et al.
NEUROSCIENCE (2012)
Glutamatergic mechanisms in the dyskinesias induced by pharmacological dopamine replacement and deep brain stimulation for the treatment of Parkinson's disease
Veronique Sgambato-Faure et al.
PROGRESS IN NEUROBIOLOGY (2012)
Synergistic antidyskinetic effects of topiramate and amantadine in animal models of Parkinson's disease
Christopher Kobylecki et al.
MOVEMENT DISORDERS (2011)
Impact of the lesion procedure on the profiles of motor impairment and molecular responsiveness to L-DOPA in the 6-hydroxydopamine mouse model of Parkinson's disease
Veronica Francardo et al.
NEUROBIOLOGY OF DISEASE (2011)
Maladaptive Plasticity of Serotonin Axon Terminals in Levodopa-Induced Dyskinesia
Daniella Rylander et al.
ANNALS OF NEUROLOGY (2010)
The α2 Adrenergic Antagonist Fipamezole Improves Quality of Levodopa Action in Parkinsonian Primates
Tom H. Johnston et al.
MOVEMENT DISORDERS (2010)
What Are the Most Important Nonmotor Symptoms in Patients with Parkinson's Disease and Are We Missing Them?
David A. Gallagher et al.
MOVEMENT DISORDERS (2010)
Effects of a NR2B Selective NMDA Glutamate Antagonist, CP-101,606, on Dyskinesia and Parkinsonism
John G. Nutt et al.
MOVEMENT DISORDERS (2008)
Animal models of Parkinson's disease and L-dopa induced dyskinesia: How close are we to the clinic?
Emma Lane et al.
PSYCHOPHARMACOLOGY (2008)
L-DOPA-induced dyskinesia: cellular mechanisms and approaches to treatment
M. Angela Cenci
PARKINSONISM & RELATED DISORDERS (2007)
The 6-hydroxydopamine model of Parkinson's disease
Nicola Simola et al.
NEUROTOXICITY RESEARCH (2007)
Metabotropic glutamate receptors in the basal ganglia motor circuit
PJ Conn et al.
NATURE REVIEWS NEUROSCIENCE (2005)
Nondopaminergic mechanisms in levodopa-induced dyskinesia
JA Brotchie
MOVEMENT DISORDERS (2005)
Sex differences in clinical and genetic determinants of levodopa peak-dose dyskinesias in Parkinson disease -: An exploratory study
M Zappia et al.
ARCHIVES OF NEUROLOGY (2005)
Continuous low-level glial cell line-derived neurotrophic factor delivery using recombinant adeno-associated viral vectors provides neuroprotection and induces behavioral recovery in a primate model of Parkinson's disease
A Eslamboli et al.
JOURNAL OF NEUROSCIENCE (2005)
A model of L-DOPA-induced dyskinesia in 6-hydroxydopamine lesioned mice: relation to motor and cellular parameters of nigrostriatal function
M Lundblad et al.
NEUROBIOLOGY OF DISEASE (2004)
Sensorimotor deficits in a unilateral intrastriatal 6-OHDA partial lesion model of Parkinson's disease in marmoset monkeys
A Eslamboli et al.
EXPERIMENTAL NEUROLOGY (2003)
Embryonic mesencephalic grafts increase levodopa-induced forelimb hyperkinesia in Parkinsonian rats
K Steece-Collier et al.
MOVEMENT DISORDERS (2003)
Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease
M Lundblad et al.
EUROPEAN JOURNAL OF NEUROSCIENCE (2002)
Functional changes of the basal ganglia circuitry in Parkinson's disease
F Blandini et al.
PROGRESS IN NEUROBIOLOGY (2000)
分享论文
